PB 133 of 2024

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 5) 2024

I, Eden Simon, as delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 11 December 2024    

Eden Simon

Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1  Name

2  Commencement

3  Authority

4  Schedules

Schedule 1—Amendments—Variation of previous determination, effective from 1 January 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

Schedule 2—Amendments commencing immediately after the commencement of Schedule 3 to the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 4) 2024

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

Schedule 3—Amendments—Additional designated brands effective from 1 June 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Name

 (1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 5) 2024.

 (2) This instrument may also be cited as PB 133 of 2024.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments—Variation of previous determination, effective from 1 January 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (table item dealing with the brand Penthrox of the drug Methoxyflurane in the form Liquid for inhalation 999 mg per g, 3 ml (with inhaler))

Omit “Penthrox”, substitute “Penthrox (Combination Pack)”.

Schedule 2—Amendments commencing immediately after the commencement of Schedule 3 to the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 4) 2024

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (table)

Omit:

Substitute:

Schedule 3—Amendments—Additional designated brands effective from 1 June 2025

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (after table item dealing with the brand Kineret of the drug Anakinra in the form Injection 100 mg in 0.67 mL single use pre-filled syringe)

Insert:

2  Section 5 (after table item dealing with the brand Cal-500 of the drug Calcium in the form Tablet, chewable, 500 mg (as carbonate))

Insert:

3  Section 5 (after table item dealing with the brand Largactil of the drug Chlorpromazine in the form Tablet containing chlorpromazine hydrochloride 25 mg)

Insert:

4  Section 5 (after table item dealing with the brand Sandrena of the drug Estradiol in the form Transdermal gel 1 mg (as hemihydrate) in 1 g sachet, 28)

Insert:

5  Section 5 (after table item dealing with the brand Estraderm MX 50 of the drug Estradiol in the form Transdermal patches 1.5 mg (as hemihydrate), 8

Insert:

6  Section 5 (after table item dealing with the brand Estraderm MX 100 of the drug Estradiol in the form Transdermal patches 3 mg (as hemihydrate), 8)

Insert:

7  Section 5 (after table item dealing with the brand Estraderm MX 25 of the drug Estradiol in the form Transdermal patches 750 micrograms (as hemihydrate), 8)

Insert:

8  Section 5 (after table item dealing with the brand Moduretic of the drug Hydrochlorothiazide with amiloride in the form Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg)

Insert:

9  Section 5 (after table item dealing with the brand Hymenoptera Honey Bee Venom of the drug Insect allergen extract-honey bee venom in the form Injection set containing 550 micrograms with diluent)

Insert:

10  Section 5 (after table item dealing with the brand Hymenoptera Paper Wasp Venom of the drug Insect allergen extract-paper wasp venom in the form Injection set containing 550 micrograms with diluent)

Insert:

11  Section 5 (after table item dealing with the brand Toujeo Solostar of the drug Insulin glargine in the form Injections (human analogue), cartridges, 300 units per mL, 1.5 mL, 5)

Insert:

12  Section 5 (after table item dealing with the brand MORPHINE SULFATE 30 mg/1 mL MEDSURGE of the drug Morphine in the form Injection containing morphine sulfate pentahydrate 30 mg in 1 mL)

Insert:

13  Section 5 (after table item dealing with the brand Lyclear of the drug Permethrin in the form Cream 50 mg per g, 30 g)

Insert:

14  Section 5 (after table item dealing with the brand Epilim Syrup of the drug Valproic acid in the form Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL)

Insert: